A detailed history of Rafferty Asset Management, LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 455,705 shares of IBRX stock, worth $2.05 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
455,705
Previous 435,653 4.6%
Holding current value
$2.05 Million
Previous $2.75 Million 38.61%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.32 - $6.7 $66,572 - $134,348
20,052 Added 4.6%
455,705 $1.69 Million
Q2 2024

Aug 13, 2024

SELL
$4.82 - $9.15 $4.22 Million - $8 Million
-874,737 Reduced 66.75%
435,653 $2.75 Million
Q1 2024

May 13, 2024

BUY
$3.23 - $6.17 $1.84 Million - $3.52 Million
570,582 Added 77.13%
1,310,390 $7.04 Million
Q4 2023

Feb 13, 2024

BUY
$1.25 - $5.21 $924,760 - $3.85 Million
739,808 New
739,808 $3.71 Million
Q4 2022

Feb 13, 2023

BUY
$4.35 - $6.77 $291,811 - $454,151
67,083 Added 16.59%
471,523 $2.39 Million
Q3 2022

Nov 14, 2022

BUY
$3.65 - $6.43 $438,430 - $772,358
120,118 Added 42.25%
404,440 $2.01 Million
Q2 2022

Aug 12, 2022

SELL
$2.68 - $6.14 $1.33 Million - $3.04 Million
-495,878 Reduced 63.56%
284,322 $1.06 Million
Q1 2022

May 13, 2022

SELL
$5.05 - $7.53 $228,199 - $340,265
-45,188 Reduced 5.47%
780,200 $4.38 Million
Q4 2021

Feb 10, 2022

BUY
$5.67 - $10.18 $2.12 Million - $3.81 Million
374,349 Added 83.0%
825,388 $5.02 Million
Q3 2021

Nov 10, 2021

BUY
$9.17 - $14.24 $305,003 - $473,636
33,261 Added 7.96%
451,039 $4.39 Million
Q2 2021

Aug 10, 2021

SELL
$13.41 - $22.4 $1.44 Million - $2.41 Million
-107,506 Reduced 20.47%
417,778 $5.97 Million
Q1 2021

May 10, 2021

BUY
$12.83 - $42.25 $6.74 Million - $22.2 Million
525,284 New
525,284 $12.5 Million

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.